SSGCID is one of two Centers funded by NIAID in response to RFP-NIAID-DMID-NIHAI2016061, RFP-NIH-NIAID-DMID-07-19, RFP-NIAID-DMID-NIHAI2011124, and RFP 75N93021R00009 and is a consortium of six institutions (Seattle Children's Research Institute, University of Washington, Hampton University, University of Kansas, Washginton University in St. Louis and Washington State University). The other funded center (CSBID) is based out of Chicago, IL. SSGCID’s primary mission is to determine the 3D atomic structures of proteins and other molecules with an important biological role in human pathogens themselves, or molecules involved in host-pathogen interactions, by applying state-of-the art high-throughput (HTP) technologies and methodologies. Pathogens include those on the NIAID Category A-C agents as well as emerging and re-emerging infectious disease organisms, each year for a period of five years. This program will also support research projects that utilize experimental approaches to better characterize the molecular mechanisms of protein targets and gain further insight into the functional roles of these targets.
SSGCID clones and proteins are available to order free of charge.
|Selection by the scientific community||Targets||Structures|
|Nominated from SSGCID selection||2192||377|
SSGCID is funded by Federal funds from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services, under Contract No.: 75N93022C00036 starting September 1, 2022. SSGCID was funded under NIAID Contracts No.: HHSN272201700059C from September 1, 2017 through August 31, 2022; HHSN272201200025C from September 1, through August 31, 2017 and HHSN272200700057C from September 28, 2007 through September 27, 2012.
Here's to our next 5 years--SSGCID launches its 16th year! Thanks to all our collaborators for your support! See ou… https://t.co/274XRLRc87
2 weeks, 6 days ago